Zacks: Brokerages Expect Bausch Health Companies Inc. (NYSE:BHC) Will Post Quarterly Sales of $2.09 Billion

Equities analysts expect Bausch Health Companies Inc. (NYSE:BHCGet Rating) to announce sales of $2.09 billion for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Bausch Health Companies’ earnings. The highest sales estimate is $2.13 billion and the lowest is $2.01 billion. Bausch Health Companies reported sales of $2.10 billion during the same quarter last year, which indicates a negative year over year growth rate of 0.5%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Bausch Health Companies will report full year sales of $8.45 billion for the current fiscal year, with estimates ranging from $8.31 billion to $8.57 billion. For the next financial year, analysts forecast that the business will post sales of $8.76 billion, with estimates ranging from $8.66 billion to $8.85 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Bausch Health Companies.

Bausch Health Companies (NYSE:BHCGet Rating) last released its earnings results on Wednesday, February 23rd. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.08 by $0.19. Bausch Health Companies had a negative return on equity of 649.29% and a negative net margin of 4.89%. The firm had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm posted $1.33 EPS. Bausch Health Companies’s revenue for the quarter was down .8% on a year-over-year basis.

Several research firms recently commented on BHC. TheStreet cut Bausch Health Companies from a “c-” rating to a “d+” rating in a research note on Monday, March 28th. StockNews.com cut Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Royal Bank of Canada lowered their price objective on Bausch Health Companies from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Sunday, May 15th. Bank of America lowered their price objective on Bausch Health Companies from $25.00 to $12.00 in a research report on Wednesday, May 11th. Finally, BMO Capital Markets lowered their price objective on Bausch Health Companies from $26.00 to $15.00 in a research report on Wednesday, May 11th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $20.80.

BHC opened at $9.93 on Monday. Bausch Health Companies has a 12 month low of $7.80 and a 12 month high of $32.54. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -8.71, a PEG ratio of 0.22 and a beta of 1.62. The business has a fifty day moving average price of $19.66 and a 200 day moving average price of $23.34.

In other Bausch Health Companies news, insider Joseph F. Gordon sold 3,889 shares of the stock in a transaction that occurred on Tuesday, March 8th. The stock was sold at an average price of $21.76, for a total transaction of $84,624.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Robert Spurr sold 1,595 shares of the stock in a transaction that occurred on Thursday, April 14th. The stock was sold at an average price of $22.19, for a total value of $35,393.05. Following the sale, the insider now directly owns 90,506 shares of the company’s stock, valued at $2,008,328.14. The disclosure for this sale can be found here. Insiders have sold a total of 16,668 shares of company stock worth $378,570 in the last 90 days. 13.75% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of BHC. WASHINGTON TRUST Co acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at approximately $28,000. Creative Financial Designs Inc. ADV lifted its holdings in shares of Bausch Health Companies by 525.0% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock valued at $29,000 after buying an additional 1,050 shares during the period. Amplius Wealth Advisors LLC acquired a new stake in shares of Bausch Health Companies in the 4th quarter valued at approximately $30,000. Glassman Wealth Services lifted its holdings in shares of Bausch Health Companies by 71.4% in the 4th quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock valued at $32,000 after buying an additional 480 shares during the period. Finally, Sargent Bickham Lagudis LLC acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at approximately $57,000. 73.38% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile (Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

See Also

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.